Effects and Safety of Growth Hormone Treatment in Six Children with Pycnodysostosis
Hormone Research in Paediatrics · 2024
DOI: 10.1159/000539574 ↗Kurz gefasst
Fallbericht in der Zeitschrift Hormone Research in Paediatrics, 2024. Verfasst von Judith Renes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Growth Research Foundation, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Pycnodysostosis, Human Growth Hormone, Body Height. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Pycnodysostosis is an extremely rare skeletal dysplasia caused by cathepsin K deficiency. It is characterized by extreme short stature with adult height (AH) in males typically less than 150 cm and in females less than 130 cm. Our objective was to evaluate the effect and safety of growth hormone (GH) treatment in 6 patients with pycnodysostosis treated according to the Dutch national pycnodysostosis guideline. Case Presentation: Six subjects (4 boys, 2 girls) presented with pycnodysostosis, treated with GH 1.4 mg/m2/day (∼0.046 mg/kg/day) for ≥1 year. Median (IQR) age at start of GH was 10.4 years (5.7; 12.2) and median height 113.5 cm (93.3; 129.3) (−4.2 SDS [−4.8; −3.6]). All children were prepubertal at start of GH. After 1 year of GH, median height gain was 7.6 cm (6.5; 8.5) (0.3 SDS [−0.3; 0.7]). Three children are still treated with GH, and the other three subjects reached AH: 1 boy reached an AH of 157.0 cm (−3.8 SDS) after 6.3 years of GH, and 2 girls reached an AH of 138.5 cm (−5.2 SDS) after 4.8 years of GH and 148.0 cm (−3.6 SDS) after 6.4 years of GH, respectively. This last girl received additional GnRH analogue treatment. In all subjects, height SDS remained stable or improved during and after GH treatment. No serious adverse advents were found. Serum IGF-I remained below the +2 SDS.
Conclusion
Our data suggest that GH may prevent the decline in height which can be observed in children with pycnodysostosis. Further research is needed to confirm this. Also, the effect of other growth-promoting strategies such as treatment with an additional GnRH analogue warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dutch Growth Research Foundation, Rotterdam, The Netherlands.
- Department of Pediatrics, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
- Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands.
- Diabeter, Centre for Pediatric and Adult Diabetes Care and Research, Rotterdam, The Netherlands.
- Department of Pediatrics, Juliana Children's Hospital/Haga Teaching Hospital, The Hague, The Netherlands.
- Department of Pediatric Endocrinology, Emma Children's Hospital, Amsterdam UMC Location, University of Amsterdam, Amsterdam, The Netherlands.
Zitieren
APA
Renes, J., Renes, J. S., Sas, T. C. J., Clement-de Boers, A., Zwaveling-Soonawala, N., Hannema, S. E., van der Velden, J. A. E. M., van der Kaay, D. C. M., & Hokken-Koelega, A. C. S. (2024). Effects and Safety of Growth Hormone Treatment in Six Children with Pycnodysostosis. Hormone Research in Paediatrics. https://doi.org/10.1159/000539574
Vancouver
Renes J, Renes JS, Sas TCJ, Clement-de Boers A, Zwaveling-Soonawala N, Hannema SE, et al. Effects and Safety of Growth Hormone Treatment in Six Children with Pycnodysostosis. Hormone Research in Paediatrics. 2024. doi:10.1159/000539574
BibTeX
@article{Renes2024,
author = {Renes, Judith and Renes, Judith S and Sas, Theo C J and Clement-de Boers, Agnes and Zwaveling-Soonawala, Nitash and Hannema, Sabine E and van der Velden, Janiëlle A E M and van der Kaay, Daniëlle C M and Hokken-Koelega, Anita C S},
title = {Effects and Safety of Growth Hormone Treatment in Six Children with Pycnodysostosis},
journal = {Hormone Research in Paediatrics},
year = {2024},
doi = {10.1159/000539574}
}
EUVIMED